Rossari Biotech reports strong Q2 FY26 revenue growth

Rossari Biotech Limited achieved revenue of Rs. 586.1 crore in Q2 FY26, an 18% year-over-year increase, fueled by healthy volume expansion in its HPPC, TSC, and AHN divisions. These divisions grew 16%, 21%, and 29% respectively. The company's international business also saw significant growth, with exports rising 36% year-over-year in Q2 and 27% in H1, contributing nearly 28% to overall revenues.

The company successfully commissioned an additional 20,000 metric tons per annum capacity at its Dahej facility and 15,000 metric tons per annum of ethoxylation capacity at Unitop. This expansion is part of a planned 30,000 metric tons per annum increase, with remaining projects expected to be capitalized in the coming months. EBITDA for Q2 FY26 stood at Rs. 71.9 crore, with a margin of 12.3%. Excluding institutional and B2C verticals, core EBITDA remained steady at around 15%.

Rossari Biotech plans to invest up to $8 million in its Saudi Arabian subsidiary, Rossari International Limited Company, to enhance its global presence. The company projects an asset turn of approximately 4x at peak utilization from its current capital expenditure, with total capital expenditure outflow of Rs. 142 crore in H1.